در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Iranian Journal of Medical Sciences
- نوع مقاله: Journal Article
- کلمات کلیدی: Mice,Probiotics,Tumor Necrosis Factor-alpha,Focal cerebral ischemia
- چکیده:
- چکیده انگلیسی: Background: Probiotics are microorganisms that may influence brain function via altering brain neurochemistry. New research evidence suggests that probiotic bacteria might protect tissue damage through diminishing the production of free radicals and/or inflammatory cytokines. Therefore, this study was designed to evaluate the effects of probiotic bacteria on the prevention or reduction of brain damage in an experimental model of stroke in mice.Methods: In this study, 30 male BLC57 mice were randomly divided into 6 equal groups. Focal cerebral ischemia was induced via middle cerebral artery occlusion for 45 minutes, followed by 24 hours of reperfusion, in the mice. Probiotics at a concentration of 107 CFU/mL were administered by oral gavage daily for 14 days before ischemia. Infarct size, neurological outcome, and biochemical markers were measured 24 hours after brain ischemia. Statistical analysis were performed using the one-way ANOVA and/or Kruskal–Wallis ANOVA on rank by Sigma Stat (2.0; Jandel Scientific) software.Results: Our results indicated that pretreatment with probiotics significantly reduced infarct size by 52% (P=0.001) but could not improve neurological function (P=0.26). Moreover, the administration of probiotics significantly decreased the malondialdehyde content (P=0.001) and the tumor necrosis factor-alpha level (P=0.004) in the ischemic brain tissue. Conclusion: The findings of the present study showed that probiotic supplements might be useful in the prevention or attenuation of brain ischemic injury in patients at risk of stroke. Probiotics may open new therapeutic alternatives for the prevention of stroke. More preclinical and clinical studies are, however, needed to clarify their efficacy in cerebral stroke.
- انتشار مقاله: 31-06-1395
- نویسندگان: Kobra Akhoundzadeh,Abedin Vakili,Mahdi Shadnoush,Jafar Sadeghzadeh
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: mesenchymal stem cell,sorafenib,Hepatocellular carcinoma,HepG2
- چکیده:
- چکیده انگلیسی: Objective: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line
systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost
the efficacy of the medication. One approach for reducing toxicity is combining sorafenib with other agents so that a
lower dose of sorafenib is required. Mesenchymal stromal cells (MSCs) can have an inhibitory effect on HCC tumor
growth. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) is the substance extracted from MSC culture and
contains most of the potential cytokines secreted by MSCs. We, therefore, anticipated a synergistic Antitumor Effect
of sorafenib in Combination with MSC-CM. In this study, we used HepG2 as our target cell lines. Methods: HepG2
cells were treated with sorafenib alone and with sorafenib + MSC-CM. CCK-8 assay was used to evaluate and compare
the inhibition of cell growth between the two groups with different treatments. Results: The combination treatment of
cell lines with sorafenib and MSC-CM had significantly reduced the values of IC50 compared to the use of sorafenib
alone (3.4 vs. 2.7 respectively). Conclusion: This study suggests that a combination of sorafenib with MSC-CM can
synergistically suppress the growth of HCC cells.- انتشار مقاله: 07-06-1397
- نویسندگان: Iman Seyhoun,Saieh Hajighasemlou,Jafar Ai,Faezeh Hosseinzadeh,Milad Mirmoghtadaei,Seyed Moein Seyhoun,Benyamin Parseh,Shahrokh Abdolahi,Zeinab Ghazvinian,Mahdi Shadnoush,Javad Verdi
- مشاهده